

## List of Tables and Figures

---

### Chapter 1

#### Introduction, Evaluation of Evidence on Mechanisms of Disease Production, and Summary

---

Table 1.1	Four-level hierarchy for classifying the strength of causal inferences from available evidence 3
Table 1.2	Causal criteria 7
Figure 1.1	The health consequences causally linked to smoking and exposure to secondhand smoke 4
Figure 1.2	General schema for the causation of disease by tobacco smoke 5
Figure 1.3	Potential pathways and mechanisms for cardiovascular dysfunction mediated by cigarette smoking 6

### Chapter 3

#### Chemistry and Toxicology of Cigarette Smoke and Biomarkers of Exposure and Harm

---

Table 3.1	Selected chronic carcinogenicity studies in mice and rats with inhalation exposure to cigarette smoke 64
Figure 3.1	Tobacco alkaloids 32
Figure 3.2	Structures of nicotine and minor alkaloid S(-)-N-methylanabasine in tobacco leaf 33
Figure 3.3	Three forms of nicotine 33
Figure 3.4	Tobacco-specific nitrosamines 35
Figure 3.5	Priority environmental polycyclic aromatic hydrocarbons 38
Figure 3.6	Commonly studied aromatic amines in tobacco smoke 42
Figure 3.7	Primary heterocyclic amines in tobacco smoke 43

### Chapter 4

#### Nicotine Addiction: Past and Present

---

Table 4.1	Criteria for substance (nicotine) dependence 106
-----------	--

Table 4.2	Questions, answers, and scoring for Fagerström Test for Nicotine Dependence and Fagerström Tolerance Questionnaire 107
Table 4.3	Measures of nicotine addiction 109
Table 4.4	Bioavailability and amount of nicotine absorbed per unit dose and time to maximum venous blood concentration of nicotine by product 113
Table 4.5	Genetic linkage studies of smoking behavior phenotypes 139
Table 4.6	Studies of candidate genes for nicotine metabolism and smoking behavior 142
Table 4.7	Studies of candidate genes for neuronal nicotine receptors and smoking behavior 144
Table 4.8	Studies of candidate genes for dopamine and smoking behavior 146
Table 4.9	Studies of candidate genes for serotonin and smoking behavior 150
Table 4.10	Other studies of candidate genes for smoking behavior 152
Table 4.11	Lifetime and current prevalence of nicotine dependence in population studies in the United States 163
Table 4.12	Prevalence of selected symptoms of nicotine dependence reported in selected studies 166
Figure 4.1	Venous blood concentrations of nicotine over time for various nicotine delivery systems 114
Figure 4.2	Mean plasma nicotine concentrations after administration of each of four smokeless tobacco products or mint snuff 115
Figure 4.3	Associative learning processes in nicotine addiction 121
Figure 4.4	Neural pathways for $\gamma$ -aminobutyric acid, glutamate, dopamine, and excitatory neurotransmitters 127
Figure 4.5	Cumulative incidence curves of daily smoking and nicotine dependence in the National Comorbidity Survey 165

Figure 4.6	Individual estimated slopes in craving ratings over three weeks prequit, from just before to just after midnight on the quit date, and over three weeks postquit 175	Table 5.12	Carcinogens and tobacco-induced cancers 299
Figure 4.7	Reactions for the three-week period before the quit date and the three-week period after the quit date 176	Figure 5.1	Link between cigarette smoking and cancer through carcinogens in tobacco smoke 226
Figure 4.8	Withdrawal severity and lapse behavior among smokers who abstained for the first five days of a quit attempt 177	Figure 5.2	Chemical structures of biomarkers of carcinogen exposure 231
Figure 4.9	Negative affect in the days and hours preceding the first lapse for smokers who attributed their first lapse to a stressor or bad mood (stress trigger) or to some other type of event (other trigger) 178	Figure 5.3	Metabolism of six carcinogens in tobacco smoke that produce DNA adducts identified in the lungs of smokers 236
<b>Chapter 5</b>			
<b>Cancer</b>			
Table 5.1	IARC evaluations of carcinogens in mainstream cigarette smoke 228	Figure 5.4	Mechanism of base excision repair 255
Table 5.2	DNA adducts in human lung tissue 243	Figure 5.5	Mechanism of nucleotide excision repair: (A) global genomic repair; (B) transcription-coupled repair 256
Table 5.3	Selected gene polymorphisms evaluated by molecular epidemiology investigations for relationship to lung cancer through variation in susceptibility to carcinogens in tobacco smoke 246	Figure 5.6	Mechanism of mismatch repair 258
Table 5.4	Human DNA glycosylases 253	Figure 5.7	Proposed mechanism of homologous recombination 260
Table 5.5	Factors involved in nucleotide excision repair activity in humans 257	Figure 5.8	Proposed mechanism of nonhomologous end-joining 261
Table 5.6	Select candidate genes and polymorphisms implicated in repair of tobacco-induced DNA damage 262	Figure 5.9	Model of mechanism for mammalian translesion synthesis 270
Table 5.7	Translesion-specialized DNA polymerases (pol) and activities on various DNA lesions 270	Figure 5.10	Patterns of <i>TP53</i> gene mutations and percentage of G→T transversion mutations in human lung cancers 278
Table 5.8	Mutational specificity of selected DNA adducts derived from tobacco smoke 271	Figure 5.11	Patterns of <i>TP53</i> gene mutations and percentage of G→T transversion mutations in different histologic types of lung cancer 280
Table 5.9	Frequency of mutation or deletion of tumor-suppressor genes in lung cancer 274	Figure 5.12	Concordance between codon distribution of G→T transversions along <i>TP53</i> gene in lung cancers (top) and distribution of adducts of benzo[ <i>a</i> ]pyrene-7,8-diol-9,10-epoxide (BPDE)-DNA adducts in bronchial epithelial cells (bottom) 281
Table 5.10	Frequency of gene amplification and increased expression of genes in lung cancer 276	Figure 5.13	Patterns of <i>TP53</i> gene mutations and percentage of G→T transversions in smoking-associated cancers other than lung cancer 282
Table 5.11	Pathways altered through gene silencing by promoter methylation 293	Figure 5.14	Tobacco-associated suppression of proapoptotic proteins and tumor-suppressor proteins 285
		Figure 5.15	Protein-signaling pathways deregulated in lung cancer 286

**Chapter 6**  
**Cardiovascular Diseases**

Table 6.1	Rate ratios for coronary heart disease among White men, by age and duration of cigarette smoking 359
Table 6.2	Death rates and rate ratios for death from coronary heart disease among men, by age and duration of smoking by number of cigarettes smoked per day 360
Table 6.3	Biomarkers of risk for cardiovascular disease from exposure to cigarette smoke 392
Table 6.4	Randomized controlled trials of counseling for smokers hospitalized with cardiovascular disease 396
Table 6.5	Randomized controlled trials of pharmacologic interventions for smoking cessation in patients with cardiovascular disease 397
Table 6.6	Smoking reduction and cardiovascular disease endpoints: biomarkers and clinical outcomes 404
Figure 6.1	Relative and excess death rate for coronary heart disease among men, by age group 356
Figure 6.2	Age-specific excess death rates among male smokers for coronary heart disease, lung cancer, chronic obstructive pulmonary disease (COPD), and cerebrovascular disease 357
Figure 6.3	Dose-response relationship between number of cigarettes smoked per day and relative risk of ischemic heart disease 358
Figure 6.4	Plasma nicotine and carboxyhemoglobin concentrations throughout a day of cigarette smoking 364
Figure 6.5	Overview of mechanisms by which cigarette smoking causes an acute cardiovascular event 366
Figure 6.6	Potential sites of actions and mechanisms of effects of smoking on platelets 376
Figure 6.7	Potential sites of effects of smoking on thrombosis through oxidative stress and other mechanisms 378

**Chapter 7**  
**Pulmonary Diseases**

Table 7.1	Causal conclusions on smoking and diseases of the respiratory tract other than lung cancer: the 2004 and 2006 reports of the Surgeon General 438
Table 7.2	Definitions for principal nonmalignant respiratory diseases caused by cigarette smoking 439
Table 7.3	Selected components of cigarette smoke and potential mechanisms of injury 439
Table 7.4	Measurements of oxidative stress 463
Table 7.5	Studies of oxidative stress in smokers 464
Table 7.6	Studies of oxidative stress in animals exposed to smoke 466
Table 7.7	In vitro studies of oxidative stress 468
Table 7.8	Genomewide linkage analysis studies in general-population samples and in families with chronic obstructive pulmonary disease (COPD) 478
Table 7.9	Replicated candidate gene associations in chronic obstructive pulmonary disease (COPD) 480
Table 7.10	Matrix metalloproteinases in emphysema 489
Table 7.11	Mouse models of overexpression of a protein leading to emphysema 492
Table 7.12	Effects of protease inhibitors in experimental smoke-induced emphysema 493
Figure 7.1	Lung defenses 440
Figure 7.2	Fractional deposition of inhaled particles in the human respiratory tract 441
Figure 7.3	Comparison of normal bronchial gland (A) with enlarged bronchial glands (B and C) from a patient with chronic bronchitis 442
Figure 7.4	Natural history of decline in forced expiratory volume with aging measured in a group of working men in West London over about six years 444
Figure 7.5	Nature of an obstruction in the small conducting airways (<2 millimeters in diameter) 445

Figure 7.6 Dose-response relationship between level of smoking and the percentage of 408 patients in the St. Paul's Lung Study with morphologic evidence of significant emphysema in their lungs 446

Figure 7.7 Postmortem bronchogram performed on the lungs of a person with centrilobular emphysema 447

Figure 7.8 Details of centrilobular emphysema lesions 448

Figure 7.9 Cut surface of lungs removed from two patients with different forms of emphysema before receiving a lung transplant 449

Figure 7.10 Innate and adaptive immune system of the lung, including the mucous production and clearance apparatus, the epithelial barrier, and the inflammatory immune response 450

Figure 7.11 Lymphoid collections within lung tissue 452

Figure 7.12 Persistent innate and adaptive immune inflammatory response in alveolar tissue 454

Figure 7.13 Remodeling process after a single clean surgical wound 455

Figure 7.14 Diagram based on three-dimensional reconstructions of serial electron micrographs illustrating how inflammatory immune cells navigate through interstitial space of alveolar wall 456

Figure 7.15 Formation of reactive oxygen species 458

Figure 7.16 Synthesis of nitric oxide (NO) and related products 459

Figure 7.17 Oxidant and antioxidant systems in the lungs 460

Figure 7.18 Pathogenesis of smoking-induced pulmonary emphysema 488

**Chapter 8  
Reproductive and Developmental Effects**

Table 8.1 Association of adult cigarette smoking and in utero exposure to cigarette smoke with semen parameters and fertility in adults 528

Table 8.2 Association between maternal smoking and spontaneous abortion (SAB), 1998–2006 532

Table 8.3 Association between maternal smoking and orofacial clefts (OFCs), 1999–2009 542

Table 8.4 Association between maternal smoking and cardiovascular malformations, by phenotype, 1999–2008 546

Table 8.5 Association between maternal smoking and non-cardiovascular congenital malformations, by type of malformation, 1998–2008 548

Table 8.6 Association between smoking and reproductive hormones in women 558

Table 8.7 Association between smoking and reproductive hormones in healthy men 562

Table 8.8 Basal maternal and fetal cardiovascular effects of smoking 569

Table 8.9 Maternal and fetal cardiovascular effects: radioisotope studies of placental intervillous blood flow (IBF) conducted before and after smoking 570

Table 8.10 Acute maternal and fetal cardiovascular effects of smoking 571

Table 8.11 Animal and in vitro studies on association between maternal smoking and congenital abnormalities with relevant genetic and/or molecular hypotheses 578

Table 8.12 Reproductive and developmental effects of polycyclic aromatic hydrocarbons (PAHs), by endpoint 590

Table 8.13 Studies of interactions between genotype and exposure to tobacco related to oral clefting 602

Table 8.14 Decreased birth weight, preterm delivery, intrauterine growth retardation, and neonatal oxidative damage: interactions between host genotype and exposure to tobacco smoke 604

**Chapter 9  
A Vision for the Future**

Table 9.1 Behavioral indicators of addiction potential of a drug or addiction to a drug 656

Figure 9.1 Effects on survival of stopping smoking cigarettes at ages 25–34 years (effect from age 35), ages 35–44 years (effect from age 40), ages 45–54 years (effect from age 50), and ages 55–64 years (effect from age 60) 649

Figure 9.2 Molecular-profiling approaches to the development of personalized therapy 650